Substrate specificity of CYP2D6 genetic variants

Area of Science:

• Pharmacogenomics
• Drug Metabolism
• Clinical Pharmacology

Background:

• Genetic variations in the Cytochrome P450 2D6 (CYP2D6) gene are crucial for guiding drug prescribing.
• Current clinical practice often overlooks the substrate-specific effects of different CYP2D6 genetic variants.

Purpose of the Study:

• To systematically investigate and characterize the substrate-specific effects of key CYP2D6 alleles (*1, *2, *10, and *17).
• To determine if known CYP2D6 variants exhibit differential activity depending on the drug substrate metabolized.

Main Methods:

• A systematic literature review was conducted to identify 22 original in vitro studies.
• Data on allele activity, defined as the ratio of clearance for the variant allele to the wild-type allele, were extracted for various CYP2D6 substrates.

Main Results:

• The CYP2D6*17 allele demonstrated substrate-specific effects, showing higher debrisoquine clearance.
• The CYP2D6*10 allele exhibited a subtle substrate-specific effect with lower dextromethorphan clearance.
• No significant substrate-specific effects were observed for the CYP2D6*2 allele across the studied substrates.

Conclusions:

• The findings support the existence of substrate specificity for certain CYP2D6 alleles, particularly CYP2D6*17 and CYP2D6*10.
• However, data for most substrates remain sparse, underscoring the need for further research to fully elucidate these pharmacogenetic interactions and optimize drug therapy.